Novavax 2024-2025 COVID-19 Vaccine Available at Major U.S. Pharmacies
On Sep. 13. 2024, Novavax announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to…
Biotechnology | COVID-19 | Life Science News | Medical Device | Medicine | Pharmaceutical | Therapeutics | Vaccine
Covid-19 pandemic changed scientific publishing
On Sep. 9, 2024, Santo Fortunato, a professor at Luddy School of Informatics, reported that an international research…
Biotechnology | Disease | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine
Emergent BioSolutions’ ACAM2000® Received U.S. FDA Approval for Mpox Indication
On Aug. 29, 2024, Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental Biologics…
Lilly opened state-of-the-art research and development center in the Boston Seaport
On Aug. 13, 2024, Eli Lilly announced the opening of the Lilly Seaport Innovation Center (LSC), a research…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Pharmaceutical | Polio | Vaccine
Novartis, Viatris face lawsuit over ‘HeLa’ cell misuse claims
On Aug. 5, 2024, Novartis and Viatris were named a federal lawsuit in Maryland by the family of…
Paxlovid led to better outcomes in hospitalized COVID cohort than Veklury or both drugs
On Jul. 24, 2024, the University of Hong Kong released a study that showed hospitalized COVID-19 patients treated…
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
On Jul. 3, 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab)…
Biotechnology | Disease | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine
Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 millionin contract modifications from the…
Novo Nordisk announced 4.1 billion USD investment to expand US manufacturing capacity
On Jun. 24, 2024, Novo Nordisk announced plans to invest 4.1 billion US dollars to build a second…
U.S. FDA Approved CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVEâ„¢ (Pneumococcal…
Agriculture | Artificial Intelligence | Biology | Biotechnology | CMO | CRO | Life Science News | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
BioMADE to Establish Bioindustrial Manufacturing Infrastructure in Minnesota
On Jun. 13, 2024, BioMADE announced an investment in a state-of-the-art bioindustrial manufacturing infrastructure in Minnesota, following support…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Life Science History | Medical Device | Neurology | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 vaccinated vs. non-vaccinated
This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…
FDA authorized Florida’s Drug Importation Program
On Jan. 5, 2024, the U.S. Food and Drug Administration authorized Florida’s Agency for Health Care Administration’s drug…
Pfizer and BioNTech received Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
On Sept. 28, 2023, Pfizer and BioNTech that Health Canada had authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Life Science News | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Vacations Redux
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in infants through active immunization of pregnant Individuals
On Aug. 21, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Disease | FDA | Pharmaceutical | Therapeutics | Vaccine
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in older adults
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellï¾’s response…
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the…
Pfizer announced acquisition of Seattle-based Seagen for $43 billion
On Mar. 13, 2023, Pfizer announced an agreement to acquire Seagen, a global biotechnology company that discovers, develops…
Pfizer’s ZAVZPRET (zavegepant) Migraine Nasal Spray received FDA approval
On Mar. 10, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant),…
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5…
Pfizer to supply global fund up to 6 million PAXLOVID treatment courses for low-and-middle-income countries
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
Biotechnology | COVID-19 | Life Science History | Life Science News | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Disease | FDA | Life Science History | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Wheel of Fortune
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…